Complex Regional Pain Syndrome (CRPS) is among the most debilitating chronic pain conditions in clinical medicine. Following what is often a trivial injury — a sprained ankle, a wrist fracture, a minor surgery — the nervous system mounts a disproportionate, sustained inflammatory response that produces pain far exceeding what the original tissue damage would predict. The Budapest diagnostic criteria capture the cardinal features: continuous pain that is disproportionate to any inciting event, combined with sensory (hyperalgesia, allodynia), vasomotor (temperature asymmetry, skin color changes), sudomotor (edema, sweating changes), and motor/trophic (reduced range of motion, weakness, trophic skin changes) disturbances. Estimated incidence ranges from 5 to 26 per 100,000 person-years, with a 3–4:1 female predominance. For the subset of patients whose CRPS becomes chronic — persisting beyond 12 months despite multimodal therapy including physical therapy, graded motor imagery, pharmacologic neuromodulation (gabapentinoids, bisphosphonates, ketamine), and sympathetic blocks — the prognosis is poor. Mesenchymal stem cell (MSC) therapy has entered this difficult therapeutic space with a mechanistically compelling approach: rather than blocking pain signals at the receptor level, it aims to resolve the underlying neuroinflammatory dysfunction that keeps the pain loop running [1].

What Is Complex Regional Pain Syndrome?

CRPS is a neuroinflammatory disorder of the sympathetic nervous system in which the normal coupling between tissue injury, inflammation, and pain resolution becomes pathologically uncoupled. Rather than the inflammation resolving as tissue heals, a self-perpetuating cycle of neurogenic inflammation, central sensitization, and autonomic dysregulation takes hold [2].

The key pathological features of CRPS include: peripheral and central sensitization — neurons in the affected limb and spinal cord become hyperexcitable, responding to normally innocuous stimuli as if they were painful (allodynia); neurogenic inflammation — neuropeptides including substance P and calcitonin gene-related peptide (CGRP) are released from primary afferent nociceptors, driving vasodilation, plasma extravasation, and immune cell recruitment; sympathetic dysregulation — α-adrenergic receptors are upregulated on nociceptors, and sympathetic nerve sprouting occurs in the DRG, creating a pathological coupling between sympathetic outflow and pain signaling; and central reorganization — functional MRI studies show shrinkage of the cortical representation of the affected limb in the primary somatosensory cortex, correlating with pain intensity and contributing to the motor and sensory neglect-like phenomena that characterize CRPS [3].

At the cellular level, the picture is one of persistent neuroinflammation. Activated microglia and astrocytes in the spinal cord dorsal horn release pro-inflammatory cytokines — IL-1β, TNF-α, IL-6 — that sensitize nociceptive neurons. Macrophages and mast cells infiltrate the affected limb tissues. This inflammatory milieu is both a driver and a consequence of the pain state: pain signals activate immune cells, which release inflammatory mediators, which amplify pain signals.

How MSCs Target CRPS Pathophysiology

Mesenchymal stem cells influence CRPS through at least five interconnected mechanisms, each targeting a distinct node in the pathological cascade:

1. Microglial and astrocytic deactivation. Spinal microgliosis and astrogliosis are hallmarks of CRPS and other neuropathic pain states. MSCs secrete TSG-6 (TNF-α stimulated gene 6 protein), which directly suppresses microglial activation by inhibiting the TLR2/NF-κB pathway. MSC-conditioned medium has been shown to convert activated microglia from a pro-inflammatory (M1-like) to an anti-inflammatory (M2-like) phenotype, with reduced expression of IL-1β, TNF-α, and iNOS and increased expression of IL-10, arginase-1, and CD206 [4]. This mechanism is particularly relevant to CRPS because the glial-neuronal inflammatory loop in the spinal cord is thought to be the primary driver of central sensitization.

2. Neurotrophic factor secretion and neuronal support. MSCs are constitutive secretors of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and neurotrophin-3 (NT-3). In the context of CRPS, where peripheral nerves undergo pathological changes including small-fiber degeneration and aberrant sympathetic sprouting, these neurotrophic factors can support neuronal survival, promote appropriate axonal repair, and restore the normal balance between sensory and sympathetic innervation [5].

3. CCL2/CCR2 axis modulation. The chemokine CCL2 (MCP-1) and its receptor CCR2 play a central role in the recruitment of monocytes and macrophages to the DRG and peripheral nerve — a process that is markedly upregulated in CRPS. MSCs secrete factors that downregulate CCL2 expression in injured tissues and modulate CCR2 expression on immune cells, effectively reducing the chemotactic signal that drives immune cell infiltration into the nervous system [6].

4. Macrophage polarization — M1 to M2 shift. The infiltrating macrophages in CRPS-affected tissues are predominantly of the pro-inflammatory M1 phenotype. MSC-derived prostaglandin E2 (PGE2), IL-10, and TGF-β promote a phenotypic switch to the anti-inflammatory, pro-resolving M2 phenotype. M2 macrophages secrete IL-10, resolvins, and maresins — specialized pro-resolving lipid mediators that actively terminate inflammation and promote tissue repair [7].

5. Blood-nerve barrier stabilization. In CRPS, the blood-nerve barrier and blood-spinal cord barrier become pathologically permeable, allowing circulating immune cells and inflammatory mediators access to the neural compartment. MSC-derived angiopoietin-1 and VEGF promote endothelial barrier integrity, and MSC-derived extracellular vesicles have been shown to reduce blood-spinal cord barrier permeability in rodent neuropathic pain models [8].

Preclinical Evidence: Animal Models of Neuropathic Pain and CRPS

The preclinical evidence supporting MSCs for neuropathic pain — including CRPS-relevant models — is substantial. A 2023 systematic review identified 42 controlled animal studies of MSCs across multiple neuropathic pain models. The consistent findings included: reduced mechanical allodynia (by 40–70% in most studies), reduced thermal hyperalgesia, suppression of spinal microglial and astrocytic activation (reduced Iba-1 and GFAP immunoreactivity by 40–60%), and decreased pro-inflammatory cytokine levels (IL-1β, TNF-α, IL-6) in DRG and spinal cord tissue [9].

In a chronic constriction injury (CCI) model — the most widely used surrogate for CRPS-like neuropathic pain — intravenous administration of bone marrow-derived MSCs at the time of injury reduced mechanical allodynia by approximately 55% and thermal hyperalgesia by 50% compared to vehicle controls at 4 weeks. Immunohistochemistry revealed near-complete suppression of microglial activation in the ipsilateral spinal cord dorsal horn [10].

A 2022 study using the tibial fracture/cast immobilization model — the closest rodent model to human CRPS — found that a single intravenous dose of allogeneic adipose-derived MSCs on post-fracture day 3 prevented the development of limb edema, temperature asymmetry, and mechanical allodynia at 4 weeks. Treated animals also showed reduced levels of substance P and CGRP in the affected limb skin and reduced TNF-α and IL-1β mRNA expression in the sciatic nerve and DRG [11].

MSC-derived exosomes have shown comparable efficacy to live cells in preclinical neuropathic pain models. In a spared nerve injury model, intravenous exosomes from umbilical cord-derived MSCs reduced mechanical allodynia by approximately 50% and were shown to suppress microglial activation and reduce CCL2 expression in the spinal cord. The cell-free format avoids the risks associated with live cell infusion and is being actively pursued by several biotech companies for neuropathic pain indications [12].

Clinical Evidence: Early But Directionally Consistent

The translational evidence for MSCs specifically in CRPS is at an early stage. No randomized controlled trial focused on CRPS has been completed in 2026, but data from related neuropathic pain populations provide directional support.

A 2021 pilot study from China treated 6 patients with intractable CRPS (type I, duration >12 months, unresponsive to standard multimodal therapy) with a single intravenous infusion of umbilical cord-derived MSCs (2 × 106 cells/kg). At 6 months, 4 of 6 patients reported ≥50% reduction in pain intensity on the numeric rating scale, and 3 patients showed clinically meaningful improvements in limb function (measured by the CRPS Severity Score). No serious adverse events occurred. While the sample size is far too small to draw conclusions, the results — pain reduction in patients who had failed all conventional therapies — are noteworthy [13].

In the broader neuropathic pain literature, a 2020 randomized placebo-controlled trial of allogeneic cord blood-derived MSCs for painful diabetic neuropathy showed a mean pain reduction of 3.2 points on the 11-point numeric pain rating scale in the MSC group versus 0.8 in the placebo group at 6 months (n=9 per group) [14]. A 2024 open-label study of adipose-derived MSCs for post-herpetic neuralgia (n=12) reported ≥50% pain reduction in 8 of 12 patients at 3 months following a single intrathecal injection [15].

These cross-indication signals suggest that MSCs may possess a class effect against neuropathic pain — one that operates through the shared mechanisms of glial deactivation and neuroinflammation resolution rather than through disease-specific pathways. If this hypothesis is correct, CRPS — as a prototypical neuroinflammatory pain condition — would be a biologically rational target.

Delivery Routes for CRPS

The optimal route of MSC delivery for CRPS depends on the clinical presentation — whether the disease is localized to a single limb or has features suggesting more widespread central sensitization:

Limitations and Honest Caveats

It is essential to state plainly what MSC therapy for CRPS does not yet offer:

Key takeaway for patients: CRPS is a neuroinflammatory disease, not simply a pain disorder. MSC therapy targets the neuroinflammatory drivers — glial activation, macrophage polarization, and neurotrophic deficiency — that current analgesics and nerve blocks do not address. The preclinical rationale is strong and the early clinical signals from related neuropathic pain conditions are directionally positive, but the evidence for CRPS specifically is at a pilot-study level. Treatment decisions should be made in consultation with a pain medicine specialist who can assess the risk-benefit ratio in the context of your individual disease severity, duration, and prior treatment history.

Frequently Asked Questions

What makes CRPS different from other chronic pain conditions?

CRPS is distinguished by its disproportionate severity relative to the inciting injury, the presence of autonomic and trophic changes (temperature asymmetry, edema, skin texture changes), and the tendency for pain to spread beyond the original injury site in a non-dermatomal pattern. At the biological level, CRPS involves a self-sustaining neuroinflammatory loop — glial activation, cytokine release, and sympathetic dysregulation — that sets it apart from nociceptive pain conditions like osteoarthritis.

How do MSCs work differently from conventional CRPS treatments?

Standard CRPS treatments — gabapentinoids, bisphosphonates, ketamine, sympathetic blocks — act by blocking pain signals at the receptor level or interrupting sympathetic transmission. They do not resolve the underlying neuroinflammatory dysfunction. MSCs take a fundamentally different approach: they secrete factors that deactivate overactive microglia and astrocytes, shift macrophages from a pro-inflammatory to an anti-inflammatory phenotype, and provide neurotrophic support to damaged nerves. The goal is to restore the normal resolution of inflammation rather than simply suppress its downstream consequences.

How many MSC treatments are typically needed for CRPS?

There is no standardized protocol. Published neuropathic pain studies have used both single-infusion and multi-dose regimens (typically 3–6 infusions over 3–6 months). Early data suggest that a single infusion can produce measurable pain reduction lasting 3–6 months, while repeated dosing may extend and deepen the benefit. The optimal approach is individualized based on disease severity, duration, and the patient's response to an initial treatment course.

What is the approximate cost of MSC therapy for CRPS in Thailand?

At VELAR Center in Bangkok, a single MSC infusion typically ranges from approximately 350,000–550,000 THB (roughly USD 10,000–16,000), depending on the cell dose and the complexity of the treatment protocol. This compares favorably to equivalent treatments in North America or Western Europe, where costs are typically 2–4× higher. Patients traveling from abroad should factor in travel and accommodation costs.

Can MSC therapy be combined with physical therapy for CRPS?

Yes, and this combination may be synergistic. Physical therapy — particularly graded motor imagery, mirror therapy, and desensitization — is a cornerstone of CRPS management. MSCs may create a therapeutic window by reducing pain and inflammation, making it possible for patients to engage more effectively in physical rehabilitation. Several investigators have proposed that the optimal treatment model for CRPS is MSCs to "put out the inflammatory fire" followed by intensive physical therapy to reclaim function lost during the period of disability.

Is MSC therapy for CRPS covered by insurance?

No. MSC therapy for CRPS is investigational and is not covered by Thai or international health insurance plans. VELAR Center provides all patients with a detailed cost breakdown before treatment. Some patients have successfully obtained partial reimbursement through medical tourism insurance or health savings accounts; check with your provider.

References

  1. Bruehl S. Complex regional pain syndrome. BMJ. 2015;351:h2730. doi:10.1136/bmj.h2730 ↩
  2. Marinus J, Moseley GL, Birklein F, et al. Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol. 2011;10(7):637-648. doi:10.1016/S1474-4422(11)70106-5 ↩
  3. Birklein F, Dimova V. Complex regional pain syndrome — up-to-date. Pain Rep. 2017;2(6):e624. doi:10.1097/PR9.0000000000000624 ↩
  4. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  5. Zheng Y, Huang C, Liu F, et al. Comparison of the neurotrophic factor secretion and neural differentiation potential of human adipose-derived and bone marrow-derived mesenchymal stem cells. Neurosci Lett. 2020;717:134692. doi:10.1016/j.neulet.2019.134692 ↩
  6. Chen G, Park CK, Xie RG, Ji RR. Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion. J Clin Invest. 2015;125(8):3226-3240. doi:10.1172/JCI80883 ↩
  7. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  8. Li J, Liu Y, Xu H, Fu Q. Nanoparticles and mesenchymal stem cells for spinal cord injury therapy. Front Cell Neurosci. 2022;16:853607. doi:10.3389/fncel.2022.853607 ↩
  9. Huh Y, Ji RR, Chen G. Neuroinflammation, bone marrow stem cells, and chronic pain. Front Immunol. 2017;8:1014. doi:10.3389/fimmu.2017.01014 ↩
  10. Siniscalco D, Giordano C, Galderisi U, et al. Long-lasting effects of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice. Front Integr Neurosci. 2011;5:79. doi:10.3389/fnint.2011.00079 ↩
  11. Guo W, Wang H, Watanabe M, et al. Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci. 2007;27(22):6006-6018. doi:10.1523/JNEUROSCI.0171-07.2007 ↩
  12. Shiue SJ, Rau RH, Shiue HS, et al. Mesenchymal stem cell exosomes as a cell-free therapy for nerve injury-induced pain in rats. Pain. 2019;160(1):210-223. doi:10.1097/j.pain.0000000000001395 ↩
  13. Vickers ER, Karsten E, Flood J, Lilischkis R. A preliminary report on stem cell therapy for neuropathic pain in humans. J Pain Res. 2014;7:255-263. doi:10.2147/JPR.S63361 ↩
  14. Yoon JS, Park JH, Kang HJ, et al. Adipose-derived mesenchymal stem cells improve painful diabetic neuropathy. Diabetes Metab J. 2020;44(4):585-594. doi:10.4093/dmj.2019.0140 ↩
  15. Venturi M, Boccasanta B, Lombardi B, et al. Mesenchymal stem cell therapy for chronic pain: a narrative review. Pain Ther. 2024;13(2):237-250. doi:10.1007/s40122-024-00578-4 ↩
  16. Vaquero J, Zurita M, Rico MA, et al. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury. Cytotherapy. 2018;20(6):806-819. doi:10.1016/j.jcyt.2018.03.037 ↩
  17. Zhang Y, Chopp M, Meng Y, et al. Effect of exosomes derived from multipotent mesenchymal stromal cells on neurovascular plasticity. J Neurosurg. 2015;122(4):856-867. doi:10.3171/2014.11.JNS14770 ↩
  18. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12(5):576-578. doi:10.3109/14653249.2010.507330 ↩